Cardiome Pharma receives approval of Kynapid
Cardiome Pharma Corp. (Nasdaq: CRME) and its co-development partner Astellas Pharma US, Inc. said late Tuesday night that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration has recommended that the FDA approve KYNAPID, a intravenous formulation of vernakalant hydrochloride, an investigational new drug for rapid conversion of acute atrial fibrillation.
Atrial fibrillation is abnormal heart rhythm.
Shares of Cardiome Pharma (CRME) climbed 9.07%, or $0.84, to $10.10 in pre-market trading. Shares of Cardiome Pharma have been trading in the range of $7.98 to $12.62 for the past 52 weeks.
